Takeda Pharmaceuticals

December 15, 2014December 17, 2014

Monash Institute and Takeda Partner Up for Gastrointestinal Research

News

The Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University in Melbourne, Australia has established a strategic research partnership with the Osaka, Japan-based research company Takeda in order to develop new drugs for the ... Read more

December 1, 2014December 1, 2014

Entyvio by Takeda UK is First UC Maintenance to Receive NICE Approval

News, Ulcerative colitis

Takeda UK, a subsidiary of Japan’s leading pharmaceutical company, recently achieved a pioneering milestone when the National Institute for Health and Care Excellence (NICE) granted Entyvio® (vedolizumab) a positive provisional recommendation in the ... Read more

November 5, 2014November 5, 2014

IBD Drug Entyvio By Takeda Pharmaceuticals Is Not Proved According to IQWiG

News

In an evaluation in accordance with the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) recently assessed whether ... Read more

October 3, 2014October 3, 2014

Further Data Support Safety, Efficacy of Takeda’s Entyvio for UC, Crohn’s

Crohn's Disease, News, Ulcerative colitis

Takeda Pharmaceuticals, which is on the forefront of treating ulcerative colitis and Crohn’s disease with the newly launched Entyvio (vedolizumab), will present data concerning the open-label extension phase 3 study ... Read more

September 30, 2014September 30, 2014

Takeda’s CD and UC Therapy Receives Positive Reaction from U.S. Gastroenterologists

Crohn's Disease, News, Ulcerative colitis

One month after the launch of Entyvio, a new treatment for moderate to severe ulcerative colitis (UC) and Crohn’s disease (CD), the therapy is already becoming a popular prescription among gastroenterologists ... Read more

July 3, 2014

Takeda’s Entyvio Approved By FDA for Ulcerative Colitis, Crohn’s Disease

Crohn's Disease, News, Ulcerative colitis

The Entyvio (vedolizumab) injection to treat adult patients with moderate to severe ulcerative colitis (UC) and Crohn‘s disease (CD) was recently approved by the U.S. Food and Drug Administration. The drug, which was ... Read more

July 1, 2014

Takeda’s New Drug for Ulcerative Colitis and Crohn’s Seen As Promising Treatment

Crohn's Disease, News, Ulcerative colitis

The recent FDA and European Commission approvals of Takeda Pharmaceuticals’ drug Entyvio for the treatment of ulcerative colitis and Crohn’s disease has given doctors and patients a promising new therapeutic option to tackle ... Read more